XML 39 R29.htm IDEA: XBRL DOCUMENT v3.26.1
Description of Business (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
May 05, 2025
USD ($)
tranche
Mar. 08, 2023
USD ($)
Oct. 31, 2024
product
Mar. 31, 2026
USD ($)
product
shares
Mar. 31, 2025
USD ($)
Mar. 03, 2026
USD ($)
Dec. 31, 2025
USD ($)
Subsidiary, Sale of Stock [Line Items]              
Operating net loss       $ 6,848 $ 15,172    
Net loss       10,674 18,892    
Net cash used in operating activities       9,952 $ 15,632    
Cash and cash equivalents       49,792     $ 53,826
Accumulated deficit       $ 671,714     $ 661,040
ATM Sales Agreement              
Subsidiary, Sale of Stock [Line Items]              
Maximum consideration receivable   $ 50,000          
Number of shares issued in transaction | shares       0      
New Pharmakon Term Loans | Line of Credit | Secured Debt              
Subsidiary, Sale of Stock [Line Items]              
Maximum borrowing capacity $ 250,000            
Number of tranches | tranche 3            
New Pharmakon Term Loans | Line of Credit | Revolving Credit Facility              
Subsidiary, Sale of Stock [Line Items]              
Maximum borrowing capacity, option $ 40,000            
A&R Loan Agreement, Tranche One | Line of Credit | Secured Debt              
Subsidiary, Sale of Stock [Line Items]              
Debt drawn 150,000            
A&R Loan Agreement, Tranche Two | Line of Credit | Secured Debt              
Subsidiary, Sale of Stock [Line Items]              
Maximum borrowing capacity 50,000            
A&R Loan Agreement, Tranche Three | Line of Credit | Secured Debt              
Subsidiary, Sale of Stock [Line Items]              
Maximum borrowing capacity $ 50,000            
Revolving Credit Facility | Line of Credit | Revolving Credit Facility              
Subsidiary, Sale of Stock [Line Items]              
Maximum borrowing capacity           $ 30,000  
Line of credit facility, accordion feature, maximum limit           10,000  
Uncommitted accordion feature, electable increment amount           5,000  
Minimum utilization threshold, amount           $ 10,000  
Symatese Europe Agreement              
Subsidiary, Sale of Stock [Line Items]              
Regulatory approval, number of products | product     3 4      
Symatese U.S. Agreement              
Subsidiary, Sale of Stock [Line Items]              
Expected regulatory approval, number of products | product       2